China Pharma Holdings reported its Q3 revenues climbed 52% to $12.61 million and net income was up 38% to $4.25 million, which equates to 10 cents per share fully diluted. Unfortunately, China Pharma is having trouble with cash flow. Its Accounts Receivables have ballooned during the first nine months of the year, rising from $19 million to $32 million, a fact that has largely offset the beneficial effects of China Pharma’s profits. More details...

Stock Symbol: (NSDQ: CPHI)